AMERICAN MEDICAL SYSTEMS, INC. v. Biolitec, Inc.

603 F. Supp. 2d 251, 2009 U.S. Dist. LEXIS 24379, 2009 WL 738858
CourtDistrict Court, D. Massachusetts
DecidedMarch 20, 2009
DocketC.A. 07-30109-MAP
StatusPublished
Cited by2 cases

This text of 603 F. Supp. 2d 251 (AMERICAN MEDICAL SYSTEMS, INC. v. Biolitec, Inc.) is published on Counsel Stack Legal Research, covering District Court, D. Massachusetts primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
AMERICAN MEDICAL SYSTEMS, INC. v. Biolitec, Inc., 603 F. Supp. 2d 251, 2009 U.S. Dist. LEXIS 24379, 2009 WL 738858 (D. Mass. 2009).

Opinion

MEMORANDUM AND ORDER REGARDING DEFENDANT’S MOTION FOR SUMMARY JUDGMENT, AND DEFENDANT’S MOTION TO PARTIALLY STRIKE OR, IN THE ALTERNATIVE, TO DISREGARD KENNETH ARNOLD’S DEPOSITION ERRATA SHEET (Dkt. Nos. 75, 73)

PONSOR, District Judge.

I. INTRODUCTION

Plaintiffs American Medical Systems, Inc. and Laserscope brought suit against Defendant Biolitec, Inc. on June 14, 2007, charging infringement of U.S. Patent No. 6,986,764 (“the '764 patent”). Dkt. No. 1. On July 31, 2008, 569 F.Supp.2d 313, the court issued its Memorandum and Order Regarding Construction of Patent Claims, Dkt. No. 63 (“Markman Order”), pursuant to Markman v. Westview Instruments, Inc., 52 F.3d 967, 976 (Fed.Cir.1995). Defendant has now moved for summary judgment.

For the reasons stated below, Defendant’s Motion for Summary Judgment, Dkt. No. 75, will be allowed. Accordingly, Defendant’s Motion to Partially Strike or, in the Alternative, to Disregard Kenneth Arnold’s Deposition Errata Sheet, Dkt. No. 73, will be denied as moot.

II. BACKGROUND

This case concerns Defendant’s alleged infringement of the '764 patent, which, generally, discloses a “Method and System for Photoselective Vaporization of the Prostate, and Other Tissue.”

The invention is useful as a treatment for Benign Prostatic Hyperplasia (“BPH”), a condition in which an enlarged prostate compromises functioning of the bladder and urethra. Vaporization, or ablation, of some of the prostate tissue allows reduction of the prostate to a smaller size.

As described in the patent, treatment of BPH using “photoselective vaporization” generally involves the insertion of a eysto-scope into the urethra, provision of a continuous flow of sterile water, and application of laser energy to the target tissue through a laser fiber. The ablation of the prostate tissue occurs holding the laser fiber 1-2 mm away from the tissue. The end point for the procedure is judged by the physician.

This procedure requires that the laser light be highly absorbed in the prostate tissue and negligibly absorbed in the irri-gant sterile water. Thus, in the Markman Order, the court construed the “photose-lective vaporization” claim limitation in the '764 patent to mean:

Using a wavelength that is highly absorptive in the tissue, while being absorbed only to a negligible degree by water or other irrigant.

Markman Order, 569 F.Supp.2d at 327.

The '764 patent prefers laser light with a wavelength of 532 nm because it exhibits *255 these photoselective properties; Plaintiffs device uses such a wavelength of laser light.

The alleged infringing device, Defendant’s Evolve laser system, produces laser light at a wavelength of 980 nm and includes a side-firing fiber optic that delivers laser energy through the side of the laser fiber. To treat BPH, the side of the fiber is placed in contact with the target prostate tissue.

The record discloses a number of metrics that may be used to measure the terms “absorptive,” “absorbed,” and “negligible,” as set forth in the Markman Order, in reference to 532 nm and 980 nm laser light as applied to prostate tissue and water. The court will not recite the scientific data put forth by the parties in detail but will summarize the relevant undisputed material facts.

First, the absorption coefficient of 980 nm laser light in water is about 0.43 while the absorption coefficient of 532 nm laser light in water is about 0.00036. Prostate tissue is mostly water and it is undisputed that the absorption coefficient of 980 nm laser light in water is at least 14 times greater than that of 532 nm laser light. 1 Second, in prostate tissue, 980 nm laser light is almost equally absorbed in water and hemoglobin. Third, approximately .004% of 532 nm laser energy is absorbed by water irrigant at a distance of 1 mm from prostate tissue while the amount of 980 nm laser light absorbed in the irrigant is over 1,100 times greater. Fourth, qualitatively, slide presentations relied upon by Defendant describe the absorption coefficient of 980 nm light in water as “low.” Finally, Defendant’s device operates by placing its laser in direct contact with prostate tissue to prevent absorption of 980 nm laser light in the water irrigant, while Plaintiffs’ device is held at a distance of approximately 1 mm from the tissue.

III. DISCUSSION

Summary judgment is appropriate if the parties’ submissions show that there is no genuine issue as to any material fact and the moving party is entitled to judgment as a matter of law. Fed.R.Civ.P. 56(c). The court views the evidence in the light most favorable to the non-moving party and the moving party bears the burden of establishing the absence of a genuine issue of material fact. Celotex Corp. v. Catrett, 477 U.S. 317, 106 S.Ct. 2548, 91 L.Ed.2d 265 (1986). In that event, the non-moving party must put forth more than a mere scintilla of evidence or evidence that is merely colorable to survive summary judgment. Anderson v. Liberty Lobby, Inc., 477 U.S. 242, 106 S.Ct. 2505, 91 L.Ed.2d 202 (1986). Though the issue of infringement is usually one for the jury, summary judgment may be granted in patent cases. See C.R. Bard, Inc. v. Advanced Cardiovascular Sys., Inc., 911 F.2d 670 (Fed.Cir.1990).

A determination of patent infringement requires that the court, first, construe a patent claim, and, second, compare it to the accused device or process. Carroll Touch, Inc. v. Electro Mechanical Sys., Inc., 15 F.3d 1573, 1576 (Fed.Cir.1993).

The court’s Markman Order constituted the first step of the infringement analysis as it construed a method or apparatus for “photoselective vaporization” of tissue to mean “using a wavelength that is highly *256 absorptive in tissue, while being absorbed only to a negligible degree by water or other irrigant.” Markman Order, 569 F.Supp.2d at 327. Thus, the claim construction has two components: (1) high absorptivity in tissue; and (2) negligible absorptivity (at most) in water or other irrigant.

This construction is the law of the case. See Markman v. Westview Instruments, Inc., 517 U.S. 370, 372, 116 S.Ct.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

American Medical Systems, Inc. v. Biolitec, Inc.
618 F.3d 1354 (Federal Circuit, 2010)

Cite This Page — Counsel Stack

Bluebook (online)
603 F. Supp. 2d 251, 2009 U.S. Dist. LEXIS 24379, 2009 WL 738858, Counsel Stack Legal Research, https://law.counselstack.com/opinion/american-medical-systems-inc-v-biolitec-inc-mad-2009.